Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association?
Parajuli
Ritesh
R
Altman
Jessica
J
Kuzel
Timothy
T
Perdekamp
Maria
M
Tallman
Martin
M
D000230:Adenocarcinoma / Q000209:etiology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000209:etiology* / Q000556:secondary; D003110:Colonic Neoplasms / Q000209:etiology / Q000601:surgery; D003111:Colonic Polyps / Q000209:etiology / Q000601:surgery; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000209:etiology*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage / Q000009:adverse effects; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D011758:Pyrroles / Q000627:therapeutic use; D012074:Remission Induction; D000077210:Sunitinib; D013997:Time Factors; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects*
D007211:Indoles; D011758:Pyrroles; D003561:Cytarabine; D014212:Tretinoin; D004317:Doxorubicin; D015122:Mercaptopurine; D000077210:Sunitinib; D008727:Methotrexate; D015255:Idarubicin; D003630:Daunorubicin